remibrutinib
Small molecule
Also known as LOU064
Evidence outlook
Approved: Chronic Spontaneous Urticaria
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also in development:Multiple Sclerosis · Phase 3Hidradenitis Suppurativa · Phase 3Secondary Progressive Multiple Sclerosis · Phase 3
Also approved (5)
- Symptomatic dermographism (SD) in adults inadequately controlled by H1 antihistamines (supplemental indication, NDA218436 S-1)
- RHAPSIDO (remibrutinib tablets) is indicated for: • the treatment of chronic spontaneous urticaria (CSU) in adult patients who remain symptomatic despite H1 antihistamine treatment.
- Rhapsido is indicated for the treatment of chronic spontaneous urticaria (CSU) in adult patients with inadequate response to H1 antihistamine treatment.
- Chronic spontaneous urticaria (CSU) in adults inadequately controlled by H1 antihistamines
- Chronic spontaneous urticaria (CSU) in adults inadequately controlled by H1 antihistamines
Development in Generalized Myasthenia Gravis stopped (2026-10-27) after a negative readout. Source
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
REMIX-1 NCT05030311 · Chronic Spontaneous Urticaria The 470 participants were randomized and quadruple-blinded to remibrutinib or placebo. At week 12, all reported primary symptom-based endpoints were met: UAS7, ISS7, and HSS7 each improved significantly more with remibrutinib than placebo (all p<0.001), supporting strong evidence from a well-controlled trial. Registry: NCT05030311 | 3 | Change From Baseline in Weekly Urticaria Score (UAS7) at Week 12 (Scenario 1 With UAS7 as Primary Efficacy Endpoint) (Baseline, Week 12); Change From Baseline in Weekly Itch Severity Score (ISS7) at Week 12 (Scenario 2 With ISS7 and HSS7 as Co-primary Efficacy Endpoints) (Baseline, Week 12); Change From Baseline in Weekly Hives Severity Score (HSS7) at Week 12 (Scenario 2 With ISS7 and HSS7 as Co-primary Efficacy Endpoints) (Baseline, Week 12) 2023-12-27 | Completed. Key figures are not recorded here; the rationale explains the result. | Reliable signal | link ↗ |
View 1 more trial
REMIX-2 NCT05032157 · Chronic Spontaneous Urticaria This was a randomized, quadruple-blind, placebo-controlled trial of 455 participants, with 2:1 assignment to remibrutinib or placebo. The prespecified clinical symptom endpoints—weekly urticaria activity, itch severity, and hives severity at Week 12—were all significantly better with remibrutinib than placebo (p<0.001), supporting strong evidence from this trial. Registry: NCT05032157 | 3 | Mean Change From Baseline in Weekly Urticaria Activity Score (UAS7) at Week 12 (Scenario 1 With UAS7 as Primary Efficacy Endpoint) (Baseline, Week 12); Mean Change From Baseline in Weekly Itch Severity Score (ISS7) at Week 12 (Scenario 2 With ISS7 and HSS7 as Co-primary Efficacy Endpoints) (Baseline, Week 12); Mean Change From Baseline in Weekly Hives Severity Score (HSS7) at Week 12 (Scenario 2 With ISS7 and HSS7 as Co-primary Efficacy Endpoints) (Baseline, Week 12) 2023-12-18 | Completed. Key figures are not recorded here; the rationale explains the result. | Reliable signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (22)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (9)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (4)
What this study did
What this study did
What this study did
What this study did
Competitive landscape
Other Bruton's tyrosine kinase (BTK) drugs
bexobrutideg, Tolebrutinib, Corubrutinib. Compare all 4 Bruton's tyrosine kinase (BTK) drugs
3 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Chronic Spontaneous Urticaria: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Remibrutinib: this drug | Approved | Small molecule | Bruton's tyrosine kinase (BTK) | Reliable signal | No reviewed efficacy summary in this indication | |
| Dupilumab (Dupixent) | Approved | Monoclonal antibody | IL-4R-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Omalizumab (Xolair) | Approved | Monoclonal antibody | IgE (immunoglobulin E), IgE | Partial signal | NCT01287117: Change From Baseline to Week 12 in the Weekly Itch Severity Score (Baseline to Week 12): Placebo -3.63 Units on a scale (Standard Deviation 5.22) | Omalizumab 75 mg -6.46 Units on a scale (Standard Deviation 6.14) | Omalizumab 150 mg -6.66 Units on a scale (Standard Deviation 6.28) | Omalizumab 300 mg -9.4 Units on a scale (Standard Deviation 5.73) NCT01292473: Change in weekly itch severity score at week 12 vs placebo (-5.14): omalizumab 75 mg -5.87, difference -0.69 (95% CI -2.54 to 1.16), p=0.4637; 150 mg -8.14, difference -3.04 (95% CI -4.85 to -1.24), p=0.0011; 300 mg -9.77, difference -4.81 (95% CI -6.49 to -3.13), p<0.0001 (CT.gov posted results). | |
| Barzolvolimab | Phase 3 | Monoclonal antibody | KIT | Partial signal | NCT06445023: Primary endpoint met: mean change from baseline in weekly urticaria activity score (UAS7) at Week 12 vs placebo; all key secondary endpoints also met (Celldex, 2026-09-22). NCT06455202: Primary endpoint met: mean change from baseline in weekly urticaria activity score (UAS7) at Week 12 vs placebo; all key secondary endpoints also met (Celldex, 2026-09-22). | |
| Bexobrutideg | Phase 3(overall) | Small molecule | Bruton's tyrosine kinase (BTK) | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| AK139 | Phase 2 | Multispecific antibody | IL-4 receptor alpha / ST2 | not yet graded | No reviewed efficacy summary in this indication | |
| CM512 | Phase 2 | Multispecific antibody | TSLP + IL-13 | not yet graded | No reviewed efficacy summary in this indication | |
| HRS-3095 | Phase 2 | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| Briquilimab | Phase 1/2 | Monoclonal antibody | KIT | not yet graded | No reviewed efficacy summary in this indication | |
| Girocitinib | —(overall) | Small molecule | TYK2/JAK1 | Reliable signal | No reviewed efficacy summary in this indication | |
| SAR449028 | —(overall) | Undisclosed | KIT | not yet graded | No reviewed efficacy summary in this indication | |
| SHR-3095 | —(overall) | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication |
Compare side by side
Upcoming events
(16 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow remibrutinib to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (6)
February 2027 (1)
What to watch
May 2027 (1)
What to watch
June 2027 (1)
What to watch
August 2027 (1)
What to watch
November 2027 (1)
What to watch
December 2027 (1)
What to watch
2028 (2)
February 2028 (1)
What to watch
May 2028 (1)
What to watch
2029 (4)
February 2029 (1)
What to watch
March 2029 (1)
What to watch
July 2029 (1)
What to watch
December 2029 (1)
What to watch
2030 (2)
2031 (1)
October 2031 (1)
What to watch
2033 (1)
January 2033 (1)
What to watch
Regulatory and conference events
(4)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent